Literature DB >> 22079050

Different binding modes of free and carrier-protein-coupled nicotine in a human monoclonal antibody.

Kaspars Tars1, Svetlana Kotelovica, Gerd Lipowsky, Monika Bauer, Roger R Beerli, Martin F Bachmann, Patrik Maurer.   

Abstract

Nicotine is the principal addictive component of tobacco. Blocking its passage from the lung to the brain with nicotine-specific antibodies is a promising approach for the treatment of smoking addiction. We have determined the crystal structure of nicotine bound to the Fab fragment of a fully human monoclonal antibody (mAb) at 1.85 Å resolution. Nicotine is almost completely (>99%) buried in the interface between the variable domains of heavy and light chains. The high affinity of the mAb is the result of a charge-charge interaction, a hydrogen bond, and several hydrophobic contacts. Additionally, similarly to nicotinic acetylcholine receptors in the brain, two cation-π interactions are present between the pyrrolidine charge and nearby aromatic side chains. The selectivity of the mAb for nicotine versus cotinine, which is the major metabolite of nicotine and differs in only one oxygen atom, is caused by steric constraints in the binding site. The mAb was isolated from B cells of an individual immunized with a nicotine-carrier protein conjugate vaccine. Surprisingly, the nicotine was bound to the Fab fragment in an orientation that was not compatible with binding to the nicotine-carrier protein conjugate. The structure of the Fab fragment in complex with the nicotine-linker derivative that was used for the production of the conjugate vaccine revealed a similar position of the pyridine ring of the nicotine moiety, but the pyrrolidine ring was rotated by about 180°. This allowed the linker part to reach to the Fab surface while high-affinity interactions with the nicotine moiety were maintained.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22079050     DOI: 10.1016/j.jmb.2011.10.042

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  4 in total

Review 1.  Development of vaccines to treat opioid use disorders and reduce incidence of overdose.

Authors:  Marco Pravetoni; Sandra D Comer
Journal:  Neuropharmacology       Date:  2019-06-04       Impact factor: 5.250

2.  An ultra-specific avian antibody to phosphorylated tau protein reveals a unique mechanism for phosphoepitope recognition.

Authors:  Heather H Shih; Chao Tu; Wei Cao; Anne Klein; Renee Ramsey; Brian J Fennell; Matthew Lambert; Deirdre Ní Shúilleabháin; Bénédicte Autin; Eugenia Kouranova; Sri Laxmanan; Steven Braithwaite; Leeying Wu; Mostafa Ait-Zahra; Anthony J Milici; Jo Ann Dumin; Edward R LaVallie; Maya Arai; Christopher Corcoran; Janet E Paulsen; Davinder Gill; Orla Cunningham; Joel Bard; Lydia Mosyak; William J J Finlay
Journal:  J Biol Chem       Date:  2012-11-12       Impact factor: 5.157

3.  Hapten-specific naïve B cells are biomarkers of vaccine efficacy against drugs of abuse.

Authors:  J J Taylor; M Laudenbach; A M Tucker; M K Jenkins; M Pravetoni
Journal:  J Immunol Methods       Date:  2014-01-23       Impact factor: 2.303

4.  Co-administration of morphine and oxycodone vaccines reduces the distribution of 6-monoacetylmorphine and oxycodone to brain in rats.

Authors:  M Pravetoni; M D Raleigh; M Le Naour; A M Tucker; T M Harmon; J M Jones; A K Birnbaum; P S Portoghese; P R Pentel
Journal:  Vaccine       Date:  2012-05-11       Impact factor: 3.641

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.